Results 21 to 30 of about 12,380 (194)
WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
Рациональная фармакотерапия в кардиологии, 2018 The aim of the review is presenting the possibilities and perspectives of the third generation of thienopyridine P2Y12 receptor inhibitor prasugrel in the treatment of patients with acute coronary syndrome (ACS).
M. Yu. Gilyarov, Е. V. Konstantinova
doaj +1 more source
Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms [PDF]
Neurointervention, 2018 Thromboembolism is one of the major complications of stent assisted coiling in treatment of cerebral aneurysm. Clopidogrel resistance is so common and prasugrel is more effective in its rapid and potent effect.
Dongwhane Lee +4 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background Management of patients with non–ST‐segment–elevation acute coronary syndrome (NSTE‐ACS) is based on 2020 European Society of Cardiology guidelines, which recommend the preferential use of prasugrel over ticagrelor. Because the selection of the
Mustafa Yildirim +7 more
doaj +1 more source
Journal of Spectroscopy, 2013 Two simple, accurate, and precise UV derivative spectrophotometric methods for the simultaneous determination of Prasugrel and Aspirin in synthetic mixture form have been developed. The first method involves measurement of second order derivative spectra
Shahabuddin N. Alvi +4 more
doaj +1 more source
BMC Cardiovascular Disorders, 2020 Background This meta-analysis aimed to compare the effects of prasugrel and ticagrelor on high (HTPR) and low on-treatment platelet reactivity (LTPR) in patients with acute coronary syndrome (ACS).
Mingxiang Wen +7 more
doaj +1 more source
Marshall Journal of Medicine, 2019 Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI.
Ahmed Amro +10 more
doaj +1 more source
Ticagrelor versus prasugrel in patients with acute myocardial infarction
, 2021 Background: Ticagrelor and prasugrel are the mainstay of antithrombotic therapy for patients with acute myocardial infarction (MI). However, direct comparative data on clinical outcomes of potent P2Y12 inhibitors are limited, especially in East Asian ...
서존 +8 more
core +1 more source
, 2015 Platelets of patients with sickle cell disease (SCD) show evidence of mild activation in the non-crisis steady state and greater activation during vaso-occlusive crises (VOC).
Lachno, D.R. +8 more
core +1 more source
Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication
Haematologica, 2015 In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor like prasugrel is prescribed for one year. Here, we investigated how the hemostatic function of platelets recovers after discontinuation of prasugrel ...
Constance C. F. M. J. Baaten +11 more
doaj +1 more source
, 2014 INTRODUCTION: Prasugrel, a P2Y₁₂ adenosine diphosphate (ADP) receptor antagonist effectively inhibits ADP-mediated platelet activation and aggregation, and may be useful in reducing vaso-occlusive crises in sickle cell disease (SCD).
Lachno, D.R. +9 more
core +1 more source